Analysis of the progression-free survival of CLL patients who received first-line bendamustine-rituximab therapy depending on the elimination rate of the minimum residual disease and mutational status IGHV genes
Titel:
Analysis of the progression-free survival of CLL patients who received first-line bendamustine-rituximab therapy depending on the elimination rate of the minimum residual disease and mutational status IGHV genes
Auteur:
Miroliubova, I. Stadnik, E. Strugov, V. Virz, Y. Nikulina, T. Tolstopiatova, E. Rumyantsev, A. Chatalava, T. Timofeeva, N. Zaritskey, A.